

# Newsletter

October 2017


## TABLE OF CONTENTS

- **TB Diagnostics Pathway** guides the way to innovation
- FIND launches diagnostic pipeline tracker
- Companion diagnostics and why we need them
- FIND commits to tackling AMR
- Changes to the WHO-FIND malaria RDT lot testing programme
- Technology & partner selection - Activity Report Q1 2016 - Q3 2017
- FIND at upcoming events
- Partner News & Resources
- Scientific articles by FIND staff & SAC
- Jobs at FIND

## TECHNICAL GUIDANCE


TPP for test predicting progression from latent to active TB

## TB Diagnostics Pathway guides the way to innovation



The **TB Diagnostics Pathway** is a virtual management tool that documents the progress of TB diagnostics and adjunct innovations from development to roll-out. Developed in collaboration with the Stop TB Partnership, the McGill International Tuberculosis Centre, Unitaid, the World Health Organization and other partners, the framework supports diagnostic innovators as well as country representatives, policy makers and community advocates. [More...](#)

## FIND launches diagnostic pipeline tracker



FIND has developed an interactive diagnostics pipeline, mapping the status and estimated release dates of diverse diagnostic solutions.



### TPP for TB sample transport solution



### FIND at World Hepatitis Summit: 1-3 Nov 2017



### End-June 2017 lot testing results

This allows stakeholders to visualize the diagnostic landscape and predict when products may be available for implementation. [More...](#)

## Companion diagnostics and why we need them




Geneva, Switzerland – 11 October 2017 – One of the targets of the United Nations' Sustainable Development Goals for 2030 is to end the tuberculosis (TB) epidemic, which demands a global effort to tackle the rise of multi-drug resistant TB (MDR TB) and extensively drug-resistant TB (XDR-TB). MDR-TB is TB that is resistant to the first-line drugs isoniazid (INH) and rifampicin (RIF), and XDR-TB is MDR-TB that has developed additional resistance to a fluoroquinolone and any of the injectable compounds used. [More...](#)

## FIND commits to tackling AMR



On 12–13 October 2017, in Berlin, Germany, FIND participated in an antimicrobial resistance (AMR) Call to Action conference, organized by the Wellcome Trust, in partnership with the governments of the UK and Thailand, and the United Nations Foundation. The event convened a wide range of global AMR stakeholders, and was designed to accelerate ongoing activity and identify critical gaps. AMR is recognised as a serious issue requiring urgent global action. [More...](#)

## Changes to the WHO-FIND malaria RDT lot testing programme





Wamboga C, Matovu E, Bessell PR, Picado A, Biéler S, Ndung'u JM. **Enhanced passive screening and diagnosis for gambiense human African trypanosomiasis in north-western Uganda – moving towards elimination.** *PLoS NTDs*, Oct 2017. [View article](#)

Rice JP, Seifert M, Moser KS, Rodwell TC. **Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting.** *PLoS ONE*, Oct 2017. [View article](#)

Serra-Casas E, Manrique P, Ding XC, Carrasco-Escobar G, Alava F, Gave A, Rodriguez H, Contreras-Mancilla J, Rosas-Aguirre A, Speybroeck N, González IJ, Rosanas-Urgell A, Gamboa D. **Loop-mediated isothermal DNA amplification for asymptomatic malaria detection in challenging field settings: Technical performance and pilot implementation in the Peruvian Amazon.** *PLoS ONE*, Oct 2017. [View article](#)

## Jobs at FIND

**Access Officer** – Diagnostic Network Optimisation (1 year contract):  
Application deadline: 10 November 2017

**Clinical Officer** – TB Team, Geneva: Application deadline: 9  
November 2017

You're receiving this email as a member of the FIND mailing list.

[Edit your subscription](#) | [Unsubscribe](#)

FIND  
Campus Biotech  
Chemin des Mines 9  
1202 Geneva  
[www.finddx.org](http://www.finddx.org)